The global market for autologous matrix-induced chondrogenesis (AMIC) is expected to witness a high level of competition in the next few years, states a new market intelligence study by Transparency Market Research. The key players in the market are focusing on the expansion of the product portfolio, which is predicted to create growth opportunities for the market players in the next few years. In addition to this, the market players are focusing on the emerging economies, which is predicted to support the growth of the global autologous matrix-induced chondrogenesis market in the next few years. Some of the leading players operating in the autologous matrix-induced chondrogenesis market across the globe are Zimmer Biomet Holdings, Smith & Nephew Plc., and Geistlich Pharma AG.